Quest Diagnostics SVP adds shares via dividend reinvestment

Quest Diagnostics Inc. executive Patrick Plewman, SVP for Diagnostic Services, reported acquiring 46 shares of Common Stock on 2026-07-22 at $206.807 per share through a dividend reinvestment plan administered by his broker.

Rhea-AI Filing Summary

Quest Diagnostics Inc. executive Patrick Plewman, SVP for Diagnostic Services, reported acquiring 46 shares of Common Stock on 2026-07-22 at $206.807 per share through a dividend reinvestment plan administered by his broker. After this small acquisition under Rule 16a-6, he directly holds 15,293 shares. The dividend reinvestment, which is eligible for deferred reporting on Form 5, has been voluntarily reported earlier on Form 4.

Insider Trade Summary

Small Acquisition: 46 shares

Small Acquisition 1 txn

Insider Plewman Patrick

Role SVP for Diagnostic Services

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock F1	46	$206.807	$10K

Holdings After Transaction: Common Stock — 15,293 shares (Direct)

Footnotes (1)

1. F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Key Figures

Shares acquired: 46 shares Price per share: $206.807 Shares held after transaction: 15,293 shares

3 metrics

Shares acquired 46 shares Common Stock acquired on 2026-07-22 under a dividend reinvestment plan

Price per share $206.807 Acquisition price for Common Stock on 2026-07-22

Shares held after transaction 15,293 shares Direct Quest Diagnostics Common Stock holdings after the reported acquisition

Key Terms

dividend reinvestment plan, Rule 16a-6, Form 5

3 terms

dividend reinvestment plan financial

"Reflects shares that were acquired pursuant to a dividend reinvestment plan administered"

A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.

Rule 16a-6 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

Form 5 regulatory

"eligible for deferred reporting on Form 5 under Rule 16a-6"

A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quest Diagnostics (DGX) executive Patrick Plewman report?

Patrick Plewman reported acquiring 46 shares of Quest Diagnostics Common Stock on 2026-07-22 at $206.807 per share. The shares were obtained through a dividend reinvestment plan and are characterized as a small acquisition under Rule 16a-6.

How many Quest Diagnostics (DGX) shares did Patrick Plewman acquire and what are his holdings now?

He acquired 46 shares of Quest Diagnostics Common Stock via dividend reinvestment. Following this transaction, Plewman directly holds 15,293 shares. These holdings reflect his position after the reported small acquisition under Rule 16a-6 on 2026-07-22.

At what price were the Quest Diagnostics (DGX) shares acquired in this Form 4 transaction?

The reported acquisition price was $206.807 per share for the 46 shares of Quest Diagnostics Common Stock. This price applies to shares acquired through a dividend reinvestment plan administered by the reporting person’s broker on 2026-07-22.

What does transaction code "L" mean in the Quest Diagnostics (DGX) Form 4?

Transaction code "L" indicates a small acquisition under Rule 16a-6. In this case, Patrick Plewman’s 46-share purchase through a dividend reinvestment plan qualifies for deferred reporting on Form 5, but he chose to disclose it earlier on Form 4.

Was the Quest Diagnostics (DGX) insider transaction reported under a Rule 10b5-1 trading plan?

No. The Form 4’s Rule 10b5-1 checkbox is not checked, indicating the transaction was not affirmed as made under a Rule 10b5-1 trading plan. The footnote instead highlights its eligibility for deferred reporting under Rule 16a-6.

Why is the Quest Diagnostics (DGX) dividend reinvestment transaction eligible for Form 5 reporting?

The footnote states the 46 shares were acquired via a dividend reinvestment plan and are eligible for deferred reporting on Form 5 under Rule 16a-6. Patrick Plewman voluntarily chose to report this small acquisition earlier on Form 4 instead.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/27/2026 - 04:34 PM Accepted by SEC EDGAR 07/27/2026 - 04:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plewman Patrick

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NEW JERSEY 07094

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP for Diagnostic Services

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/22/2026		L	V	46(1)	A	$206.807	15,293	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney in Fact for Patrick Plewman	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)